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Dried Blood Spot Analysis for Therapeutic Drug Monitoring of
Linezolid in Patients with Multidrug-Resistant Tuberculosis
D. H. Vu,a,b,c M. S. Bolhuis,b R. A. Koster,b B. Greijdanus,b W. C. M. de Lange,d R. van Altena,d J. R. B. J. Brouwers,a D. R. A. Uges,b and
J. W. C. Alffenaarb
University of Groningen, Department of Pharmacotherapy and Pharmaceutical Care, Groningen, The Netherlandsa; University of Groningen, University Medical Center
Groningen, Department of Hospital and Clinical Pharmacy, Groningen, The Netherlandsb; Hanoi University of Pharmacy, Hanoi, Vietnamc; and University of Groningen,
University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlandsd
Linezolid is a promising antimicrobial agent for the treatment of multidrug-resistant tuberculosis (MDR-TB), but its use is lim-
ited by toxicity. Therapeutic drug monitoring (TDM)may help to minimize toxicity while adequate drug exposure is main-
tained. Conventional plasma sampling andmonitoring might be hindered in many parts of the world by logistical problems that
may be solved by dried blood spot (DBS) sampling. The aim of this study was to develop and validate a novel method for TDM of
linezolid inMDR-TB patients using DBS sampling. Plasma, venous DBS, and capillary DBS specimens were obtained simultane-
ously from eight patients receiving linezolid. A DBS sampling method was developed and clinically validated by comparing DBS
with plasma results using Passing-Bablok regression and Bland-Altman analysis. This study showed that DBS analysis was re-
producible and robust. Accuracy and between- and within-day precision values from three validations presented as bias and co-
efficient of variation (CV) were less than 17.2% for the lower limit of quantification and less than 7.8% for other levels. The
method showed a high recovery of approximately 95% and a lowmatrix effect of less than 8.7%. DBS specimens were stable at
37°C for 2 months and at 50°C for 1 week. The ratio of the concentration of linezolid in DBS samples to that in plasma was 1.2
(95% confidence interval [CI], 1.12 to 1.27). Linezolid exposure calculated from concentrations DBS samples and plasma showed
good agreement. In conclusion, DBS analysis of linezolid is a promising tool to optimize linezolid treatment inMDR-TB pa-
tients. An easy sampling procedure and high sample stability may facilitate TDM, even in underdeveloped countries with limited
resources and where conventional plasma sampling is not feasible.
Linezolid is used as a second-line drug in the treatment of mul-tidrug-resistant tuberculosis (MDR-TB) due to its efficacy in
vitro (21), in vivo (9), and in patients (1, 2, 14, 17, 34) against
Mycobacterium tuberculosis. The World Health Organization
(WHO) classifies linezolid as a reserve antituberculosis drug for
the treatment of multidrug-resistant/extensively drug-resistant
tuberculosis (MDR/XDR-TB) (33). Linezolid is usually added to a
treatment regimen consisting of antituberculosis drugs to which
M. tuberculosis is still susceptible. However, treatment with line-
zolid may be limited by toxicity, such as time- and dose-depen-
dent neuropathy or myelosuppression (17, 29), which leads to
dose reduction or cessation of treatmentwith linezolid. Therapeu-
tic drugmonitoring (TDM) can be used to implement dose reduc-
tions to limit toxicity while preventing inadequate exposure. Effi-
cacy predicting pharmacokinetic/pharmacodynamic (PK/PD)
parameters, such as the ratio of the area under the concentration-
time curve from 0 to 24 h to theMIC (AUC0–24/MIC), might be
helpful in evaluating linezolid dosages (1, 7, 26, 32). The
AUC0–24/MIC has been shown to be the best predictive model
in amurinemodel (32), but evidence from human data is lacking.
Further PK/PDdata fromTBprograms or large studies are needed
for the development of evidence-based PK/PD parameters, such
as an AUC0–24/MIC target ratio.
Linezolid treatment has been evaluated for TB treatment in
several case series (17, 23). However, neither drug susceptibility
tests (DSTs) nor drug exposure assessment was performed for
linezolid, making it difficult to draw conclusions about efficacy
(5). For instance, drug interactions with other antimicrobial
agents might have occurred and might have had an impact on
linezolid exposure (6, 15). In addition, conventional drug expo-
sure evaluation for TB drugs using plasma samples might have
been hindered in these studies by logistical challenges (30). The
use of dried blood spot (DBS) sampling may provide a helpful
alternative to conventional plasma sampling through a simplified
sampling procedure and increased sample stability. DBS sampling
has been applied in the treatment of other infectious diseases like
malaria and HIV (30). Other advantages of DBS samples may
include the requirement of a lower blood sample volume and
lower biohazard risk than for conventional plasma samples (12,
18, 30). Compared to conventional sampling, DBS sampling may
be hindered by inter- and intrapatient hematocrit (Hct) variation
which leads to different blood viscosity values, yielding a propor-
tional analytical bias withHct values. Furthermore,Hctmay affect
the drug blood/plasma partition ratio, complicating the compar-
ison with conventional plasma samples. In the development of a
bioanalytical method for linezolid using DBS analysis, important
patient-related factors like blood spot volume, Hct value (3, 24),
and difference between capillary and venous blood have to be
assessed during validation (12, 18, 25, 30). To enable individual-
ized linezolid treatment, the aim of this study was to develop and
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validate amethod forDBS analysis and evaluate it inMDR-TB and
XDR-TB patients.
MATERIALS AND METHODS
Patients. From September 2010 to March 2012, MDR-TB patients (18
years old) were recruited from the Tuberculosis Centre Beatrixoord, Uni-
versity Medical Center Groningen (Haren, The Netherlands). Eligible for
inclusion were patients receiving treatment with antituberculosis drugs
for which routine therapeutic drug monitoring was scheduled. Patients
with bleeding disorders were excluded from the study. The study proce-
dures were reviewed and approved by the local ethics committee. Patients
receiving linezolid were included after providing written informed con-
sent.
Sampling was performed at least 1 week after the start of linezolid
treatment to ensure that the steady state was achieved. Venous blood
samples were obtained before drug intake and at 1, 2, 3, 4, and 8 h after
dosing according to a previous study (2) and to local procedures for TDM
of TB drugs to be able to calculate drug exposure and other PK parame-
ters. Venous dried blood spot (VDBS) specimens were prepared by pi-
petting 50 l of venous blood onto Whatman 31 ET CHR paper. The
remaining venous blood was centrifuged at 3,000 rpm for 5 min at room
temperature to obtain plasma, which was stored at20°C until analysis.
DBS specimens were obtained through a finger prick by dropping the
blood directly on dried blood spot paper. DBS samples were obtained
before drug intake and at 2 and 8 h after dosing, representing low, high,
and medium linezolid blood levels, respectively. Both the VDBS and DBS
samples were left to dry at room temperature and stored in sealed plastic
bags with desiccant sachets at20°C until analysis.
DBS analysis. To quantify DBS samples, an 8-mm-diameter disc was
punched out of each blood spot. Extraction of these discs was performed
by sonication with a frequency of 47 kHz for a period of 20 min using 500
l of extracting solvent consisting of 0.3 mg/liter cyanoimipramine (in-
ternal standard) and 1g/liter EDTA inwater. From this solution, a volume
of 200 l was added to 750 l of acetonitrile. The samples were vortexed
for 1 min and subsequently centrifuged at 11,000 rpm for 5 min. An
injection volume of 5l was analyzed using a validated liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) analysis method (16).
The plasma samples were prepared and analyzed using the same method.
DBS analytical method validation. The DBS analytical method was
validated in accordance with the U.S. Food and Drug Administration
(FDA) guidance for bioanalytical method validation (27). For the valida-
tion, blood was prepared by mixing plasma and red blood cell and
linezolid stock solution to achieve blood at the desired concentration and
Hct level. Subsequently, the validation DBS samples were prepared by
pipetting 50 l of blood onto the paper. Linearity was assessed with 1/x2
weighting over a linezolid concentration range of 0.05 to 40 mg/liter.
Clinical relevant concentrations were well within the range of the assay
standards (2). The within-day and between-day accuracy and precision
were evaluated on four validation levels, that is, lower limit of quantifica-
tion (LLOQ), low, medium, and high, at linezolid concentrations of 0.05,
0.25, 15, and 30 mg/liter, respectively. Each validation level was analyzed
in five replicates on three consecutive days. The matrix effect and the
recovery of linezolid fromDBS sampleswere determinedusing a common
method (18, 31). The stability of DBS specimens was assessed by storing
validation DBS samples under ambient conditions and at 37°C after 1
week, 2weeks, and 2months. As aworst-case scenario, the stability ofDBS
specimens was also assessed at 50°C after 1 day, 2 days, and 1 week. The
stability was evaluated at low and high levels of linezolid in five replicates
by comparing the analytical results with the nominal concentrations. In
addition to the criteria suggested in the FDA guideline (27), the impact on
assay accuracy and precision due to the variations of Hct values and blood
spot volumes were evaluated. For these purposes, Hct values of 20, 25, 30,
35, 40, 45, and 50% and blood spot volumes of 30, 50, 70, and 90 l were
assessed. During the method validation, blood spot volume and Hct val-
ueswere standardized at 50l and 35%, respectively. Setting theHct value
at 35% reflects the Hct in tuberculosis patients (3).
Pharmacokinetic and pharmacodynamic evaluation. Pharmacoki-
netic parameters were evaluated using a noncompartmental model of the
KINFIT module of MW Pharm (version 3.9; Mediware, The Nether-
lands). The AUC from 0 to 12 h (AUC0–12) was calculated using the
trapezoidal rule from 0 up to 12 h, and the AUC0–24 was calculated by
doubling the AUC0–12. The maximum concentration (Cmax) was defined
as the highest observed linezolid concentration, and the corresponding
time atwhich this valuewas reachedwas designatedTmax. The elimination
half-life (t1/2) was calculated by dividing the natural logarithm of 2 (ln2)
by the elimination constant (ke), as calculated byMWPharm. The appar-
ent clearance (Cl) of linezolid was calculated by dose/AUC0-12. The vol-
ume of distribution (Vd) was calculated by dividing Cl by ke.
The drug susceptibility testing of the Mycobacterium tuberculosis iso-
lates was performed at the Dutch National Mycobacteria Reference Lab-
oratory (National Institute for Public Health and the Environment
[RIVM]) using the Middlebrook 7H10 agar dilution method (28). The
AUC0-24/MIC ratio, often used as a predictive pharmacodynamic param-
eter for efficacy, was calculated (32).
Statistics. In the method validation, the bias was defined as the differ-
ence (in percentage) between the analytical result and the nominal con-
centration. The method was clinically validated by comparing the
linezolid concentrations in DBS and VDBS samples with the concentra-
tion in plasma using Passing-Bablok regressions and Bland-Altman anal-
ysis by applying the software tool Analyze-it, version 2.20 (Analyze-it
Software, Ltd.). Conversion factors, calculated from geometric mean
(V)DBS/plasma concentration ratios, were used to calculate converted
DBS and VDBS concentrations (4). Subsequently, the converted concen-
trationswere used to calculate theAUC0-12 for linezolid inDBS andVDBS
samples. The agreement between AUC0-12 values for converted linezolid
concentrations in DBS and plasma was evaluated using Bland-Altman
analysis. The Spearman correlation and Wilcoxon signed-rank test was
applied to other comparisons.
RESULTS
Patients. Eight patients with a median age of 29 years (interquar-
tile range [IQR], 24 to 33 years) were included in this study. The
baseline characteristics are presented in Table 1. The median Hct
value was 37.4% (IQR, 33.0 to 41.4%). During the study, three of
eight patients received linezolid at 300 mg twice a day and five
patients received a dose of 600 mg twice daily. Isolates of seven
patients showed resistance to the first-line drugs isoniazid, rifam-
pin, ethambutol, pyrazinamide, and streptomycin. The isolate of
one patient showed resistance to all first-line drugs except pyrazi-
namide. All DSTs revealed resistance to rifabutin, whereas one
isolate showed fluoroquinolone resistance, and three showed pro-
tionamide resistance. None of the patients experienced significant
discomfort from the finger pricks during DBS sampling, which
was supported by the fact that all completed the three consecutive
samples in this study.
DBS method validation. The DBS assay method showed lin-
earity over the analytical concentration range. The pooled corre-
lation coefficient, r2, was 0.9947. The regression equation is as
follows: concentration  (0.1635  0.0025)  response 
(0.0001  0.0003). Within-day and between-day accuracy and
precision showed coefficients of variation (CVs) within accepted
ranges. Within-day CVs ranged from 1.6% to 13.8%, and be-
tween-day CVs were from 3.5% to 10.2%. The mean measured
concentration was within 98.7% to 106.3% of the nominal con-
centration. The bias caused by variable matrices, i.e., DBS and
EDTA matrices, was less than 8.7%. The recovery of DBS extrac-
tion was between 94.1% and 97.2%. No significant linezolid deg-
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radation was observed after DBS samples were stored at 50°C for
at least 1week and at 37°Cor ambient temperature for 2months as
biases were less than 15%.
Variation of blood spot volume between 30 l to 90 l had a
minor impact on the assay accuracy as the bias ranged from
11.6% to 7.1%. The variation of Hct levels from 20% to 50%
yielded biases within 7.6% to 6.8% and 12.5% to 5.7% for
medium and high linezolid concentration levels. Larger biases of
17.8% to 11.9% were observed at the low concentration level
(0.25 mg/liter) (Table 2).
Comparisons of DBS, VDBS, and plasma analyses. Signifi-
cant proportional biases were observed in Passing-Bablok regres-
sions in which the slope of regression line for linezolid concentra-
tions betweenDBS samples and plasmawas 1.28 (95% confidence
interval [CI], 1.13 to 1.44) andbetweenVDBS samples andplasma
was 1.46 (95% CI, 1.40 to 1.54). The intercepts were0.42 (95%
CI,1.72 to 0.17) and0.67 (95% CI,1.36 to0.09), respec-
tively (Fig. 1). In Bland-Altman analysis, the geometric mean
linezolid concentration ratios in DBS and VDBS samples versus
plasma were 1.20 (95%CI, 1.12 to 1.27) and 1.36 (95%CI, 1.32 to
1.40), respectively. The ratio ofVDBS/plasmawas higher than that
of DBS/plasma (Wilcoxon signed-rank test, n  24, P  0.01).
Limits of agreement of 95% were shown, with less than 5% of the
values falling out of the ranges (Fig. 2).
Pharmacokinetic and pharmacodynamic evaluation. Me-
dian AUC0–12 values for linezolid in plasma were 50.9 (IQR, 50.5
to 54.9) mg · h/liter following a dose of 300 mg and 126 (IQR,
121.6 to 127.6) mg · h/liter following a dose of 600 mg. Linezolid
pharmacokinetic parameters are shown in Table 3. The concen-
tration-time curves for linezolid in plasma, DBS, and VDBS are
presented in Fig. 3.
TABLE 1 Baseline demographics of study patients (n 8)
Parameter Value
Age (yr) 29 (24–33)a
Sex (no. of patients)
Male 2
Female 6
Bodyweight (kg) 60.5 (55.8–61.5)a
Height (m) 1.69 (1.67–1.76)a
Body mass index (kg/m2) 20.1 (19.0–21.4)a






Hemoglobin (mmol/liter) 7.0 (6.4–8.8)a,b
Hematocrit (%) 37.4 (33.0–41.4)a,c









a Median value (IQR).
b Reference values for healthy subjects, 7.5 to 9.9 mmol/liter (female) and 8.7 to 10.6
mmol/liter (male).
c Reference values for healthy subjects, 37.0 to 47.0% (female) and 42.0 to 52.0%
(male).
d n/N, number of TB patients with other infections/total number of TB patients.
TABLE 2 Summarized results of the validation of DBS analysis
Validation criterion
Validation level (n 5)e
LLOQ Low Medium High
Nominal linezolid
concentration (mg/liter)
0.05 0.25 15 30
Reproducibilitya
Accuracy (bias [%]) 4.5 6.3 3.2 1.3
Within-day precision
(CV [%])
13.8 4.0 4.1 1.6
Between-day precision
(CV [%])
10.2 3.5 6.1 7.7
Overall precision
(CV [%])
17.2 5.3 7.4 7.8
Matrix effect (%) 2.9 8.7 1.9
Recovery (%) 95.5 94.1 97.2
Effect of blood vol (range of
bias [%])b
2.9–4.1 11.4–7.1 11.6–9




1 week at 50°C (bias [%]) 6.7 3.4
2 mos at 37°C (bias [%]) 10 5.9
2 mos at ambient temp
(bias [%])
2.5 2.0
a Data are from three separate validation days.
b Comparison with sample of standardized blood spot volume (35 l).
c Comparison with samples of standardized hematocrit (35%).
d Present data are from the last time point of the stability test only.
e n, number of replicates.
FIG 1 Passing-Bablok regression between measurements in DBS/VDBS sam-
ples and plasma: VDBS-plasma regression line (dashed line,), slope of 1.46
(95% CI, 1.40 to 1.54) and intercept of 0.67 (95% CI, 1.36 to 0.09);
DBS-plasma regression line (solid line,Œ), slope of 1.28 (95%CI, 1.13 to 1.44)
and intercept of0.42 (95% CI,1.72 to 0.17).
Vu et al.
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The AUC0–12 values for linezolid in DBS and VDBS were cal-
culated using the conversion factors 1.20 and 1.36 for DBS and
VDBS, respectively. The subsequent results showed a good agree-
ment with plasma. All the values were within the 95% limit of
agreement (Fig. 4). The individual data for each patient for
AUC0–12 attained from plasma and converted (V)DBS concentra-
tions and the respective AUC0–24/MIC values are presented in
Table 4. Patients that received a linezolid dose of 300 mg twice
daily (n 3) had a median AUC0–24/MIC ratio in plasma of 236
(IQR, 219 to 322), and patients that received 600 mg twice daily
(n 5) had a median AUC0–24/MIC ratio in plasma of 508 (IQR,
486 to 1,398).
DISCUSSION
This study showed that DBS analysis is an easy tool to individual-
ize MDR-TB treatment with linezolid. In addition, this report
presents a novel, validatedmethod of analysis of linezolid in dried
blood spots, with specimens that proved to be very stable over
time.
In previous studies on DBS analysis of other drugs, several
technical factors were pointed out that have to be considered
when interpreting DBS analysis, such as the effect of Hct and
blood spot volume (12, 13, 18, 30). For the analysis of linezolid in
DBS samples, the effect of Hct seemed to be of minor concern. In
this study, biases fell within accepted ranges for Hct values be-
tween 20 and 50%. These Hct values cover an even broader range
than clinical Hct values found in TB patients in literature, i.e.,
35.4% 6.7% (3) and in this study 37.4% 4.4%. Based on these
findings, the standardization ofHct at 35%duringDBS validation
is acceptable. Furthermore, variation of blood spot volume be-
tween 30 and 90 l had little effect as biases were within 15%.
Despite the minor influence of technical factors, i.e., Hct value
and blood spot volume, physiological factors are also mentioned
in literature to possibly limit the applicability and interpretation
of DBS analysis (13). Such a factor might be differences between
the concentration of linezolid in plasma and that in whole blood.
This study shows that concentration of linezolid is higher in blood
than in plasma. This is caused by different capacities of binding to
plasma proteins and blood cells. Furthermore, concentrations of
linezolidwere higher inVDBS than inDBS samples. Thismight be
caused by differences between the capillary and venous blood (13,
25, 30). Nevertheless, the linezolid concentrations in both DBS
and VDBS specimens showed good correlation with the plasma
concentration. To compensate for these differences, we propose
conversion factors of 0.83 (1/1.20) for DBS and 0.74 (1/1.36) for
VDBS to calculate corresponding plasma values. After the conver-
sion, good agreement between the AUC0–12 h values for linezolid
in DBS samples and plasma was observed.
A meta-analysis showed that a 600-mg linezolid daily dose
resulted in lower frequency of either an adverse event or adverse
events necessitating treatment discontinuation than a dose of
FIG 2 Bland-Altman plot of linezolid concentration ratios in DBS and VDBS
samples versus plasma: solid line, mean ratio; dashed line, limit of agreement
(mean ratio 1.96 standard deviation of the ratio).
TABLE 3 Steady-state pharmacokinetic parameters of linezolid in
plasmaa
Parameter
Value for the parameter by linezolid dosea
300 mg (n 3) 600 mg (n 5)
AUC0–12 (mg · h/liter) 50.9 (50.5–54.9) 126.9 (121.6–127.6)
Cmax (mg/liter) 8.8 (7.8–8.9) 16.5 (14.4–16.5)
Tmax (h) 1.9 (1.9–4.8) 1.9 (1.7–3.0)
t1/2 (h) 4.6 (4.0–6.9) 7.5 (7.3–7.9)
Cl (liters/h) 4.9 (3.8–5.1) 3.1 (3.0–3.1)
Vd (liters) 32.6 (29.4–34.4) 34.8 (32.9–41.6)
a Data are presented as medians (IQR). All patients (n 8) received linezolid twice
daily.
FIG 3 Concentration-time curves of linezolid in plasma (, solid line), VDBS
samples (Œ, dashed line), andDBS samples (▫, dotted line). Plasma andVDBS
data are presented as means and standard deviations. For visual purposes, the
DBS data are presented as means without error bars.
FIG 4 Bland-Altman plot of AUC0–12 for linezolid from correctedDBS versus
AUC0–12 plasma samples. Solid line, mean difference; dashed line, limit of
agreement (mean difference 1.96 standard deviation of the difference).
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600 mg daily (8). Among the published data, the lowest rate of
adverse effects was observedwith a dose of 300mg once daily (17).
Nevertheless, lowering the dose clearly results in lower exposure
to the drug (2, 19). In addition, interpatient variability and possi-
ble drug-drug interactions may lead to under- or overexposure.
Therefore, treatment with a fixed dosemay be questionable (6, 11,
22, 26). The application of TDM for linezolid can help avoid un-
der- or overexposure, which may occur in 30 to 40% of the cases
(20).
In this study, all patients had Mycobacterium tuberculosis iso-
lates with a linezolidMIC of0.5mg/liter.With a dose of 600mg
(n  5) twice daily, very high AUC0-24/MIC ratios were reached
(10), so dose reductions could be implemented to prevent time-
and dose-dependent toxicity. Furthermore, a high correlation of
AUC0-24/MIC values between converted values for DBS and
plasma (Spearman’s rho 0.976, n 8) was observed. This sug-
gests that TDMusing DBSmay result in interventions identical to
those with conventional plasma sampling. Therefore, adaptive
dosing of linezolid to prevent potential toxicity and to ensure ther-
apeutic exposure is feasible using DBS sampling.
The high stability ofDBS specimens canminimize the logistical
burden of conventional sampling in limited-resource areas. With
simple instructions, the DBS samples can be obtained easily and
sent to equipped facilities for analysis by mail (12, 30). This could
allow TDM in TB programs worldwide, including in resource-
limited settings where an MDR/XDR-TB epidemic is a growing
problem. TDMusing DBS sampling forMDR/XDR-TB should be
especially considered in areas where HIV or malaria coinfections
are highly prevalent asDBS sampling has been successfully applied
to monitor the treatment of such diseases (30).
Since treatment of MDR/XDR-TB is long and complicated by
adverse drug reactions, TDM of linezolid with DBS sampling
could be used to optimize drug exposure during treatment. In
conclusion, this study presents a novel, validated analysis of
linezolid in DBS specimens that is suitable for optimization of
linezolid treatment of MDR-TB. Advantages include a very
simple, low-biohazard-risk samplingmethod using a finger prick,
easy logistics, and very good stability of DBS specimens.
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